TLDR
- Hims & Hers stock surged 12-16% on October 15 after launching a menopause and perimenopause care program targeting 1.3 million U.S. women annually.
- Shares are up 110-115% year-to-date in 2025, trading around $62.80 and vastly outperforming competitors like Teladoc.
- The FDA issued warning letters in September over weight-loss drug promotions, causing 6-7% stock declines.
- Wall Street consensus remains “Hold/Reduce” with Bank of America maintaining a $28 price target, implying 55% downside potential.
- The Hers platform serves 500,000+ subscribers with projected revenue exceeding $1 billion by 2026.
Hims & Hers Health stock posted a strong rally on October 15 following the company’s expansion into menopause care. The telehealth platform launched a new specialty on its Hers platform for women experiencing perimenopause and menopause.
Shares jumped 12-16% on heavy trading volume. About 29 million shares changed hands, roughly 15 times the daily average. The stock closed near $61, marking one of the strongest single-day performances in recent months.
The new service fills a healthcare gap. Approximately 1.3 million women enter menopause annually in the U.S. Yet only 30% of OB/GYN residency programs provide formal menopause training.
Women can now access licensed providers through the platform. Treatment plans include prescription medications like estradiol for hot flashes and progesterone for sleep quality. Options come in pills, patches, and creams based on individual health history.
“This isn’t just about medication ā it’s about building and growing a platform that women can trust to access the care they need,” said Jessica Shepherd, chief medical officer of Hers.
Stock Performance and Growth Trajectory
Hims & Hers shares have more than doubled in 2025. The stock is up 110-115% year-to-date, trading around $62.80 as of October 16. That represents a 7% gain for the day and about 5% growth over the past month.
The performance crushes traditional telehealth competitors. Hims & Hers is up roughly 158% in 2025 while rival Teladoc has fallen 44%. The company now holds a market cap of $13-14 billion.
The stock hit an all-time high of $72.98 in February 2025. Current prices sit about 19% below that peak.
The Hers platform currently serves over 500,000 subscribers. Management projects the platform will exceed $1 billion in annual revenue by 2026. This follows September’s rollout of low-testosterone treatment plans for men.
Regulatory Pressure and Analyst Outlook
The stock faces regulatory headwinds. The FDA condemned a Hims & Hers Super Bowl commercial in mid-September for promoting GLP-1 weight-loss drugs without listing risks.
The agency then issued warning letters accusing the company of making unapproved drug copies. The stock dropped 6-7% after these letters became public.
The FTC is also investigating Hims over marketing and subscription practices. That news triggered a 5% stock decline.
Wall Street remains divided. Of 14 analysts tracked, only 2 rate the stock a Buy. Nine hold it at Hold while 3 rate it a Sell.
Bank of America analyst Allen Lutz maintains a Sell rating with a $28 price target. That implies 55% downside from current levels. His concerns include rising customer acquisition costs and regulatory impacts on margins.
Canaccord Genuity takes an optimistic view with a Buy rating and $68 price target. The firm cites rapid specialty expansion and strong user engagement.
Average analyst targets cluster around $39 on MarketBeat. Simply Wall St’s cash flow model pegs fair value at $62.47. However, the forward P/E ratio of 63x remains high compared to sector averages.
Investors await third-quarter earnings on November 3. In Q2 2025, Hims grew subscribers 31% year-over-year to 2.44 million. Management has reiterated 2025 guidance of $2.35 billion in revenue with 11.5% EBITDA margin.
The company has expanded aggressively beyond core offerings. It moved into weight-loss drugs last year, selling compounded semaglutide when branded options were scarce. The direct-to-consumer model covers sexual health, hair loss, dermatology, and fertility needs.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
